(Q38151738)

29 August 2017

title

Cancer immunotherapy: accomplishments to date and future promise (English)

1 reference

29 August 2017

1 reference

Karim Y Helmy

1

1 reference

29 August 2017

Shyam A Patel

series ordinal

2

1 reference

29 August 2017

George R Nahas

series ordinal

3

1 reference

29 August 2017

Pranela Rameshwar

series ordinal

4

1 reference

29 August 2017

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

4

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1307-1320

1 reference

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

29 August 2017

cites work

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

Cancer; a biological approach. I. The processes of control

21 January 2018

1 reference

Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience.

21 January 2018

1 reference

Cancer incidence and risk factors after solid organ transplantation

21 January 2018

1 reference

Identification of human cancers deficient in antigen processing

21 January 2018

1 reference

Targeting natural killer cells and natural killer T cells in cancer

21 January 2018

1 reference

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

21 January 2018

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

21 January 2018

1 reference

Transforming growth factor-beta and the immune response to malignant disease

21 January 2018

1 reference

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

21 January 2018

1 reference

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma

21 January 2018

1 reference

Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment

21 January 2018

1 reference

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma

21 January 2018

1 reference

Can immuno-oncology offer a truly pan-tumour approach to therapy?

21 January 2018

1 reference

The spontaneous regression of cancer. A review of cases from 1900 to 1987.

21 January 2018

1 reference

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

Denileukin diftitox: a novel immunotoxin

21 January 2018

1 reference

Immunotherapy: past, present and future

21 January 2018

1 reference

Antibody-based immunotherapy of cancer

21 January 2018

1 reference

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends

21 January 2018

1 reference

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

21 January 2018

1 reference

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

21 January 2018

1 reference

Antibody therapy of cancer

21 January 2018

1 reference

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

Prediction of response to anticancer immunotherapy using gene signatures

21 January 2018

1 reference

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

21 January 2018

1 reference

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

21 January 2018

1 reference

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

Next generation of immunotherapy for melanoma

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Prostate cancer vaccines: Update on clinical development

21 January 2018

1 reference

Prostate cancer vaccines in clinical trials

21 January 2018

1 reference

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer

21 January 2018

1 reference

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

21 January 2018

1 reference

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

Graft-versus-leukemia effects of transplantation and donor lymphocytes

21 January 2018

1 reference

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy

21 January 2018

1 reference

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

Trial Watch: Adoptive cell transfer immunotherapy

21 January 2018

1 reference

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

21 January 2018

1 reference

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

21 January 2018

1 reference

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

21 January 2018

1 reference

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

21 January 2018

1 reference

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

Genetically engineered T cells for the treatment of cancer

21 January 2018

1 reference

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

21 January 2018

1 reference

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

Paths to stemness: building the ultimate antitumour T cell.

21 January 2018

1 reference

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression

21 January 2018

1 reference

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells

21 January 2018

1 reference

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

21 January 2018

1 reference

Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells

21 January 2018

1 reference

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

21 January 2018

1 reference

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

21 January 2018

1 reference

Specificity in cancer immunotherapy

21 January 2018

1 reference

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

21 January 2018

1 reference

Oncolytic viruses for induction of anti-tumor immunity

21 January 2018

1 reference

Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer

21 January 2018

1 reference

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy

21 January 2018

1 reference

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.

21 January 2018

1 reference

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer

21 January 2018

1 reference

Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment

21 January 2018

1 reference

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/TDE.13.88

1 reference

29 August 2017

1 reference